drugset / Trial / NCT04614142

Single Patient Protocol for Donor HCV-positive to Recipient HCV-negative Kidney Transplant in a Patient at Risk for Loss of Dialysis Access

NCT04614142

Phase 4 Withdrawn Massachusetts General Hospital
NaSingle-groupOpen-labelPrevention

Summary

This is a single patient, single center study evaluating if administration of pan-genotypic DAA therapy on day 3 (+/- 2 days) post-kidney transplant prevents the transmission of hepatitis C virus infection from an HCV-positive donor kidney to an HCV-negative recipient.

Timeline

Start
2020-11-13
Primary completion
2021-08-04
Completion
2021-08-04

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject glecaprevir Other / unclassified 100 mg Oral
Subject glecaprevir Other / unclassified 300 mg Oral
Subject pibrentasvir Other / unclassified 40 mg Oral
Subject pibrentasvir Other / unclassified 120 mg Oral